Latest

$CB Chubb wrote fourteen billion dollars of insurance this quarter and walked away from the business that did not pay — Chubb earned $6.82 per share on an 84% combined ratio while deliberately non-renewing mispriced property business. The underwriting culture is the moat. • $RVMD Pancreatic Cancer Just Got Its First Real Punch Against KRAS. The Survival Numbers Are Not Small. — Daraxonrasib delivered a hazard ratio of 0.40 in the Phase 3 RASolute 302 trial, nearly doubling median overall survival in previously treated metastatic pancreatic cancer. Gene rates RVMD a Buy. • $IDYA IDEAYA's Eye Cancer Drug Just Got the Biggest Stage in Oncology. The Scoreboard Looks Real. — IDEAYA's darovasertib combo cut progression risk 58% in the first randomized trial for HLA-A2-negative metastatic uveal melanoma. Now the full dataset heads to ASCO's main stage. • The SpaceX S-1 Is a Blueprint for a Civilization-Scale Company — SpaceX's now-public S-1 reveals $18.67B in revenue, a $1.75T target valuation, dual-class control for Musk, and a 30% retail allocation that could reshape the IPO market. • $TSLA Tesla's Robotaxi Just Went Unsupervised in Three Texas Cities. The Price War With Waymo Is Already Over. — Tesla launched fully driverless rides in Dallas and Houston, undercutting Waymo by 56% on price, with Cybercab mass production starting this month and seven cities targeted by June. • $CB Chubb wrote fourteen billion dollars of insurance this quarter and walked away from the business that did not pay — Chubb earned $6.82 per share on an 84% combined ratio while deliberately non-renewing mispriced property business. The underwriting culture is the moat. • $RVMD Pancreatic Cancer Just Got Its First Real Punch Against KRAS. The Survival Numbers Are Not Small. — Daraxonrasib delivered a hazard ratio of 0.40 in the Phase 3 RASolute 302 trial, nearly doubling median overall survival in previously treated metastatic pancreatic cancer. Gene rates RVMD a Buy. • $IDYA IDEAYA's Eye Cancer Drug Just Got the Biggest Stage in Oncology. The Scoreboard Looks Real. — IDEAYA's darovasertib combo cut progression risk 58% in the first randomized trial for HLA-A2-negative metastatic uveal melanoma. Now the full dataset heads to ASCO's main stage. • The SpaceX S-1 Is a Blueprint for a Civilization-Scale Company — SpaceX's now-public S-1 reveals $18.67B in revenue, a $1.75T target valuation, dual-class control for Musk, and a 30% retail allocation that could reshape the IPO market. • $TSLA Tesla's Robotaxi Just Went Unsupervised in Three Texas Cities. The Price War With Waymo Is Already Over. — Tesla launched fully driverless rides in Dallas and Houston, undercutting Waymo by 56% on price, with Cybercab mass production starting this month and seven cities targeted by June. •

Disclosures

Important information about StockJungle content

StockJungle is an investment media platform. All content is for informational purposes only and does not constitute financial advice.

Content Disclosure

All articles, analysis, investment theses, and commentary on StockJungle are produced by our 13 portfolio managers. Their opinions, predictions, and analyses should not be treated as expert financial advice.

Model Portfolios

The model portfolios tracked on StockJungle are hypothetical and simulated. They do not represent actual trading accounts or real money positions. Model portfolio performance:

Does not reflect actual trading costs, slippage, or market impact
Does not account for taxes or regulatory constraints
Is calculated based on hypothetical trades that may not be executable in real markets
Past performance does not guarantee or indicate future results

Not Investment Advice

Nothing on StockJungle constitutes:

A recommendation to buy, sell, or hold any security
An offer or solicitation to purchase or sell securities
Professional financial, tax, or legal advice
A guarantee of any particular investment outcome

Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Risks of Investing

Investing in securities involves risk of loss. The value of investments can go down as well as up. You could lose some or all of your invested capital. Different investment strategies carry different levels of risk, and there is no guarantee that any strategy will achieve its objectives.

Data Accuracy

While we strive for accuracy, StockJungle cannot guarantee that all market data, financial figures, or analyses are completely accurate or up to date. Market data may be delayed and should not be relied upon for time-sensitive trading decisions.

No Fiduciary Relationship

Use of StockJungle does not create a fiduciary, advisory, or professional relationship between you and StockJungle or its operators. We do not know your individual financial situation, risk tolerance, or investment objectives.

Regulatory Status

StockJungle is not a registered investment advisor, broker-dealer, or financial institution. We are a media platform that publishes content about financial markets.